Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
IMRX
Upturn stock ratingUpturn stock rating

Immuneering Corp (IMRX)

Upturn stock ratingUpturn stock rating
$3.04
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: IMRX (4-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Above Average Performance

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Number of Analysts

rating

5 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $11.25

1 Year Target Price $11.25

Analysts Price Target For last 52 week
$11.25 Target price
52w Low $1.01
Current$3.04
52w High $4.69

Analysis of Past Performance

Type Stock
Historic Profit 262.83%
Avg. Invested days 40
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 109.40M USD
Price to earnings Ratio -
1Y Target Price 11.25
Price to earnings Ratio -
1Y Target Price 11.25
Volume (30-day avg) 5
Beta 0.37
52 Weeks Range 1.01 - 4.69
Updated Date 08/15/2025
52 Weeks Range 1.01 - 4.69
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.9

Earnings Date

Report Date 2025-08-13
When -
Estimate -0.42
Actual -0.4

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -57.9%
Return on Equity (TTM) -102.48%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 87041596
Price to Sales(TTM) 563.62
Enterprise Value 87041596
Price to Sales(TTM) 563.62
Enterprise Value to Revenue 191913.54
Enterprise Value to EBITDA -1.53
Shares Outstanding 35985700
Shares Floating 27205191
Shares Outstanding 35985700
Shares Floating 27205191
Percent Insiders 24.35
Percent Institutions 12.41

ai summary icon Upturn AI SWOT

Immuneering Corp

stock logo

Company Overview

overview logo History and Background

Immuneering Corp. was founded in 2008. It's a biopharmaceutical company focusing on developing and commercializing transformative therapies to treat cancer patients.

business area logo Core Business Areas

  • Drug Development: Developing new therapies based on biological insights and computational approaches.

leadership logo Leadership and Structure

Executive leadership includes Diana Brainard, M.D. as CEO. Organizational structure is typical of a clinical-stage biotech firm, with departments focused on research, development, clinical trials, and business operations.

Top Products and Market Share

overview logo Key Offerings

  • IMM-1-104: An oral MEK inhibitor being developed for advanced RAS mutant solid tumors. Phase 1/2a clinical trials are ongoing. No current market share as it is still in development. Competitors include other MEK inhibitors in development.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry, specifically oncology, is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. There is a large unmet need for novel cancer therapies.

Positioning

Immuneering is positioned as a targeted oncology drug developer, aiming to address specific unmet needs in RAS mutant solid tumors. Competitive advantages include their unique computational approach to drug discovery.

Total Addressable Market (TAM)

The global market for cancer therapies is estimated at hundreds of billions of dollars. Immuneering is focusing on subsets of this market, particularly RAS mutant cancers. The specific TAM for their drug candidates will depend on the successful completion of clinical trials and subsequent regulatory approvals.

Upturn SWOT Analysis

Strengths

  • Novel computational drug discovery platform
  • Experienced management team
  • Promising pre-clinical and clinical data
  • Targeting specific unmet medical needs

Weaknesses

  • Limited financial resources compared to larger pharmaceutical companies
  • Reliance on successful clinical trial outcomes
  • High risk of drug development failure
  • Single product pipeline

Opportunities

  • Potential partnerships with larger pharmaceutical companies
  • Expansion of pipeline into other oncology indications
  • Positive clinical trial results leading to regulatory approval
  • Advancements in computational drug discovery

Threats

  • Clinical trial failures
  • Competition from other pharmaceutical companies
  • Changes in regulatory landscape
  • Intellectual property challenges
  • Economic downturn affecting investment in biotechnology

Competitors and Market Share

competitor logo Key Competitors

  • ARRY
  • RDHL
  • TAK

Competitive Landscape

Immuneering faces competition from established pharmaceutical companies and other biotech firms developing oncology therapies. Their computational platform offers a potential advantage, but clinical trial success is crucial.

Growth Trajectory and Initiatives

Historical Growth: Immuneering's historical growth is characterized by progress in pre-clinical and early clinical development. Revenue growth is not a primary focus at this stage.

Future Projections: Future growth depends on successful clinical trial outcomes for IMM-1-104 and other pipeline candidates. Analyst estimates are available from financial news sources and research reports.

Recent Initiatives: Recent initiatives include advancing IMM-1-104 through clinical trials and exploring new drug targets using their computational platform.

Summary

Immuneering Corp is a high-risk, high-reward clinical-stage biopharmaceutical company. The company has a unique computational platform for drug discovery. Their success hinges on the outcomes of clinical trials, particularly for IMM-1-104. The company needs to manage its cash burn rate and secure further funding. Potential partnerships can further de-risk development.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Financial news sources
  • Analyst reports

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual risk tolerance and thorough research.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Immuneering Corp

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 2021-07-30
Co-Founder, President, CEO & Director Dr. Benjamin J. Zeskind M.B.A., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 54
Full time employees 54

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.